Ajanta Pharma Ltd (AJANTPHARM) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 42842.30 Cr. Figures below are as reported and are shown with their source and date.
Ajanta Pharma Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 7,713 full-time employees. The company went IPO on 2000-06-05. The firm provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The firm is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. The company has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The firm's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
Source: finedge · as of 2026-09-29
Last close (₹): 3,270.6
Source: quantro_screener_metrics_job · as of 2026-10-22
Source: quantro_screener_metrics_job · as of 2026-10-23
| Year ended | Revenue (₹ Cr) | PAT (₹ Cr) | EPS (₹) |
|---|---|---|---|
| Mar 2026 | 5,452.86 | 1,056 | 84.52 |
| Mar 2025 | 4,648.1 | 920.39 | 73.68 |
| Mar 2024 | 4,208.71 | 816.17 | 64.82 |
| Mar 2023 | 3,742.64 | 587.98 | 45.89 |
| Mar 2022 | 3,340.99 | 712.68 | 55.62 |
Source: finedge · as of 2026-07-21
Source: finedge · as of 2026-03-31
Source: quantro_company_profiles · as of 2026-10-23
Figures computed 2026-10-23.